Search Results

High-content screening (HCS) has become a cornerstone in GPCR and phenotypic drug discovery, enabling researchers to quantify cellular responses with spatial, temporal, and mechanistic depth. For GPCR-focused programs, the ability to visualize receptor localization, internalization kinetics, and ligand interactions in intact cells offers advantages that extend far beyond traditional biochemical or radioligand assays. Yet, despite remarkable progress, HCS workflows remain vulnerable to several performance-limiting factors: variable cell behavior, imaging artifacts, batch effects, and incomplete assay optimization. These challenges can obscure real biological signals and complicate the identification of robust hits. Overcoming them requires careful assay design and strategic use of the right fluorescent probes. In this blog, you’ll learn:  How HCS works and why it is increasingly central to GPCR-based drug discovery  The key phases of designing a reproducible HCS workflow  How fluorescent ligands strengthen assay robustness and biological relevance What Is High-Content Screening and Why It Matters for GPCR Programs High-content screening integrates automated microscopy, multiplexed imaging, and computational analysis to evaluate cellular responses under chemical or genetic perturbations. Unlike biochemical assays, which reduce biology to a single readout, HCS captures whole-cell phenotypes and single-cell heterogeneity. Modern HCS instruments combine robotics, high-speed imaging, environmental control, and image-analysis pipelines capable of extracting hundreds of features per cell. The resulting multiparametric datasets are well-suited for GPCR research, where receptor trafficking, spatial dynamics, and context-dependent signaling significantly influence pharmacology. For GPCR assay developers, HCS supports:  Quantitative visualization of receptor internalization and trafficking  • Live-cell kinetic measurements  unavailable to endpoint assays  Multiplexed assessment of pathway activation   Improved confidence in hit prioritization through phenotypic fingerprints HCS is also becoming critical in toxicity screening, mechanistic target validation, and ligand profiling—making it an essential tool across the GPCR drug discovery pipeline. Why Traditional Radioligand Methods Fall Short for Modern Screening Needs Radioligand binding assays have historically been the standard for GPCR pharmacology. However, their limitations become increasingly important as drug discovery moves toward high-information, high-throughput formats. Key limitations of radioligand assays include:  • No spatial information  — signals are measured in bulk, masking subcellular dynamics  • Low temporal resolution  — difficult to use in kinetic or live-cell experiments  • Regulatory and safety constraints  that complicate workflows  • High waste-disposal requirements  • Reduced compatibility with phenotypic screening frameworks By contrast, HCS-based ligand binding assays—especially those enabled by next-generation fluorescent ligands—support:  Repeated imaging for equilibrium measurements  High-resolution spatial localization  Multiparametric phenotypic profiling  Full compatibility with automated screening infrastructure  Safer and more sustainable workflows For GPCR researchers aiming to reduce ambiguity in early hit-finding, the shift from radioligands to fluorescent HCS assays offers substantial scientific and operational benefits. The Phases of a Reliable HCS Workflow Designing a robust HCS assay requires a structured, iterative approach. The following phases minimize batch effects, reduce imaging artifacts, and strengthen reproducibility. 1. Assay Design and Pilot Optimization Successful HCS begins with a clearly defined biological question and the careful selection of a physiologically relevant cell model. Pilot experiments are essential to optimize:  Cell density  Fluorescent probe concentration  Exposure times and illumination settings  Imaging channel configurations The goal is to achieve a high Z′ factor , reflecting assay robustness and dynamic range. Early optimization prevents later variability and sets the foundation for scalable screening. 2. Plate Layout and Sample Handling Automated liquid handlers and randomized plate layouts are used to minimize positional effects and edge-related artifacts. Incorporating internal controls, including known agonists or antagonists, allows normalization and facilitates detection of plate-level drift. Probe panels—such as lysosomal dyes or cytoskeletal markers—can be integrated to support multiplexed readouts and mechanistic interpretation. 3. Imaging Calibration and Acquisition These steps ensure that quantitative signals reflect biology, not instrument variation. Imaging instruments must be calibrated for:  Focus stability  Light-path alignment  Illumination homogeneity  Spectral separation Environmental control (CO₂, humidity, temperature) prevents drift during long acquisition runs. 4. Image Processing and Feature Extraction Once images are acquired, segmentation algorithms convert them into quantifiable data. Increasingly, deep-learning-based segmentation  is becoming the standard for capturing single-cell features such as morphology, intensity, and localization. Retaining single-cell data preserves heterogeneity and enables mechanistic analyses, particularly important for GPCR signaling where subpopulations often drive distinct responses. 5. Data Analysis, Normalization, and Hit Identification Dimensionality reduction, batch correction, and standardized normalization methods prepare data for hit selection. Multivariate scoring allows integration of multiple phenotypic features, improving the robustness of hit identification relative to single-endpoint measures. When executed as a unified pipeline, these phases ensure an HCS assay capable of supporting both exploratory phenotypic screens and targeted GPCR binding studies. Figure 1. Standard HCI experimental pipeline. (A) After experimental design, wet lab work is performed to acquire high-content cell images, which then require several canonical image analysis steps. Cell segmentation is optional, but it will allow single-cell profiling downstream. (B) After image featurization,  image-based profiling steps are performed to prepare data for downstream analyses. (C) This full pipeline is orchestrated by reproducible software tools to ensure data provenance and to enable benchmarking. Source: Way GP, Sailem H, Shave S, Kasprowicz R, Carragher NO. Evolution and impact of high content imaging. SLAS Discov. 2023 Oct;28(7):292-305.  How Fluorescent Ligands Strengthen HCS Assays: The Case of CELT-331 Fluorescent ligands are now considered the gold standard for image-based GPCR assays. Their ability to visualize ligand–receptor interactions directly in living cells produces data that are both more physiologically relevant and more reproducible than traditional methods. Key scientific advantages include: Physiological Relevance Fluorescent ligand binding occurs in intact cells, preserving receptor conformation, trafficking, and native membrane context—key variables for GPCR pharmacology. Cleaner Signal and Higher Specificity Modern fluorophores minimize background, enabling precise quantification of binding and displacement curves. Non-Radioactive Workflow By removing isotopes, researchers gain safer, more scalable, and more environmentally responsible workflows. Visual + Quantitative Data Fluorescent ligand assays generate both numerical values (IC₅₀, Kᵢ) and spatial information that clarifies receptor behavior under different ligand conditions. Case Study: CELT-331 in CB2 High-Content Binding Assays In CB2-expressing HEK cells, the fluorescent ligand CELT-331  produces precise membrane-localized binding signals. When combined with a competitor such as the CB2-selective partial agonist GW40583, displacement curves can be visualized and quantified directly through HCS microscopy. This approach improves readout clarity, strengthens data reproducibility, and enables kinetic or equilibrium measurements impossible in endpoint radioligand assays. Figure 2. CB 2  cannabinoid high-content competition binding screening experiments with CELT-331. CB 2 -expressing HEK cell lines are labeled with CELT-331 at 80 nM (right), while competition with the CB 2 -selective partial agonist GW40583 is studied (left) to measure competitor binding affinity.  For cannabinoid researchers, this capability supports:  Accurate CB2 affinity determination  Visualization of ligand binding dynamics  Scalable, reproducible high-throughput assays  A smoother transition from screening to mechanistic studies At Celtarys, these capabilities are provided as a complete CB2 HCS service—allowing teams to integrate fluorescent ligand technologies without needing internal imaging infrastructure or specialized assay development expertise. Conclusion High-content screening continues to reshape GPCR drug discovery, offering richer biological context, improved assay sensitivity, and more confident identification of lead candidates. But fully leveraging HCS requires rigorous assay design, careful imaging calibration, and the strategic use of high-performance fluorescent ligands. As shown through the CELT-331 case study, fluorescent ligand–enabled HCS workflows provide physiologically relevant, reproducible, and multiparametric insights that traditional methods cannot match. For teams working in GPCR pharmacology or cannabinoid research, these tools accelerate hit validation, reduce ambiguity, and support more data-driven decision-making across early discovery. Looking ahead, combining HCS with advanced probe design, scalable analytics, and expert scientific support will further strengthen its role across the drug discovery ecosystem. At Celtarys, we remain committed to enabling this transition and supporting researchers as they design and optimize their next generation of cell-based assays. 👉 Learn more about CELT-311 References Booij TH, Price LS, Danen EHJ. 3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis. SLAS Discov.  2019.  Lin S, Schorpp K, Rothenaigner I, Hadian K. Image-based high-content screening in drug discovery. Drug Discov Today. 2020.  Way GP et al. Evolution and impact of high content imaging. SLAS Discov.  2023.

Burning Cash Isn’t the Problem. Burning Alignment Is. Every biotech founder fears the day the cash runs out. You track the burn rate. You watch the runway shrink. You delay hires. You negotiate term sheets from a place of panic. But here’s what most founders miss. 👉 Cash isn’t your biggest problem. Misalignment is. Not the obvious kind either. We’re not talking about personality clashes or investor drama. 👉 We’re talking about the type of quiet misalignment that appears to be progress but feels like confusion . The team is moving. The calendar is full. The experiments are running. But when you zoom out, you’re not actually getting closer to your next strategic inflection point . That’s what we call the hidden burn . 👉 This post breaks down how biotech misalignment happens, what it costs you, and how to fix it before your runway disappears without a clear outcome to show for it. Scientific progress doesn’t guarantee startup success; strategic clarity does. Where Biotech Misalignment Starts 👉 Most misalignment doesn’t start with conflict. It starts with silence. You assume your CSO knows where you’re headed. You assume the board is aligned with milestones. You assume your cofounder sees the same finish line you do. They don’t. 👉 Biotech misalignment usually begins when scientific logic and business logic quietly diverge . At first, it’s just different vocabulary. Later, it becomes different roadmaps. And by the time you catch it, your burn rate is up and your traction is down. Here are the three most common sources of internal drift in early biotech teams: 1️⃣ Scientific versus commercial vision 👉 Your science team optimizes for validation. Your business team optimizes for traction. If no one owns the connection between the two, they pull in opposite directions . Example: You validate a biomarker for a broad indication. Your BD person starts framing it for a niche diagnostic use. The board expects an IND package. No one’s wrong, but no one’s aligned. 2️⃣ Founder-team decision asymmetry 👉 The founders make strategic calls in 1:1s or ad hoc Slack threads. The team only finds out when timelines shift. This breeds passive execution, second-guessing, and a lack of ownership . People stop thinking ahead because they don’t know what’s coming. 3️⃣ Silent conflict inside your SAB or board 👉 Scientific advisors disagree with your go-to-market direction. Investors push for speed. No one wants to say it out loud. You end up running two strategies in parallel . One in your deck. One in your team’s head. How Misalignment Drains Your Runway 👉 Misalignment doesn’t show up as chaos. It shows up as wasted momentum. Your team is working. Your lab is busy. Your timelines look full. But the wrong things are moving. Or the right things are moving in the wrong order. 👉 That’s how biotech teams burn through capital without hitting real inflection points . Here’s how it happens: 1️⃣ Duplicated effort 👉 Two teams think they’re building toward the same milestone. In reality, they’re solving different problems. You pay for both. You benefit from neither. Example: Your platform team is building a modular assay framework. Your clinical lead is already assuming a fixed diagnostic protocol. By the time it surfaces, you’ve lost two months of budget and alignment. 2️⃣ Milestone redefinition spiral 👉 The milestone was “complete preclinical package by Q3.”Then it became “optimize lead series.”Then “refine bioavailability model.”Then “add a secondary endpoint.” The date never changed. But the scope moved. And now your next raise is behind schedule. 3️⃣ Strategic dilution 👉 You keep adding just one more use case. Just one more backup program. Just one more exploratory study. Your story gets fuzzy. Your team gets stretched. Your capital gets fragmented. Investors don’t fund complexity. They fund momentum. And misalignment kills momentum in slow, silent, irreversible ways. Real biotech traction starts when decisions are driven by shared strategy, not disconnected deliverables. Fixing the Alignment Problem Before It Kills Your Strategy Biotech misalignment does not fix itself. It does not go away with more meetings, louder all-hands sessions, or rewritten pitch decks. 👉 It only gets resolved when you rebuild how decisions are made and what truly matters inside your company. 1️⃣ The first shift is reframing what you call a milestone. A milestone is not a scientific phase. A milestone is a decision point that moves your company in a strategic direction. If nothing changes after it, it was just a lab update. Not progress. 👉 If your roadmap is full of scientific deliverables but empty of decision triggers, you’re burning runway without building value. 2️⃣ The second shift is clarifying roles, not titles. Most biotech founders don’t suffer from having the wrong people. They suffer because everyone has a different idea of what their role actually is.   Your CSO is not your COO. Your SAB is not your operating committee. Your cofounder is not your board. When these lines blur, so do accountability and execution. 3️⃣ The third and hardest shift is restoring shared context. Not by overexplaining. Not by trying to align on every single choice. But by making the decision framework visible across the team.  People don’t need to vote on everything. They just need to understand what game they’re playing. Here’s the truth biotech founders miss. Alignment is not a culture topic. It’s a leverage tool. ✅ When you fix alignment, you free up speed, clarity, and execution, without adding headcount or budget. Realignment as a Growth Lever, Not Just a Fix 👉 Most founders treat alignment like a hygiene issue. Something to clean up when it gets bad enough. A background process. A soft skill. ✅ But in biotech, alignment is a multiplier. When your team is aligned, you move faster without more funding. You adapt quicker without losing direction. You communicate with investors without rewriting your story every month. ✅ Science doesn’t just advance. It connects to business outcomes. Some of the most promising biotech teams aren’t failing; they’re just stuck. They have strong early data and an even stronger burn rate. Everyone’s busy. No one’s clear. But the moment they shift from disconnected workstreams to a shared, milestone-driven roadmap tied to strategic decisions, not just scientific deliverables, momentum changes. ✅ Realignment unlocks clarity. Clarity attracts capital. And suddenly, it becomes obvious what to kill and what to scale. ✅ That’s the power of strategic realignment. It’s not just damage control. It’s how biotech companies move from drift to direction. Conclusion: Don’t Let Misalignment Drain Your Future Misalignment rarely announces itself. It doesn’t crash your system. It just slowly redirects energy, delays clarity, and erodes momentum. 👉 You don’t notice it until you’re out of time, out of cash, and out of direction. But if you catch it early and fix it decisively, alignment becomes one of your strongest strategic assets. 👉 Not because it makes everyone agree. But because it ensures everyone is solving the same problem. ✅ If your biotech startup feels like it’s moving but not advancing, the issue might not be speed. It might be a direction. Ready to Break Your Bottlenecks? If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

Watch Episode #177 The Experiment That Was Never Meant to Succeed When David Hodson’s lab teamed up with chemist Johannes Broichhagen aka JB, the goal was bold and elegant: Create a photo-switchable ligand to remotely control GPCR signaling with light. This was the moment when photopharmacology felt like the future. The literature was buzzing. Labs were competing. The idea was simple — turn signaling on or off with a flash of light. Except: Nothing behaved. Receptor access was unpredictable. Tissue responses defied the model. They had a tool that did bind the GPCR… but not in the light-controlled way they wanted. Most labs would have stopped there — archived the data, moved on, written it off as a failed bet. They didn’t. Sometimes the things you think are going to end up on the cutting-room floor become the best work. Instead of abandoning the compound, the team did something different: they looked at what it could do, not what it failed to do. And that shift changed everything. The Moment a Failed Tool Became a GPCR Imaging Breakthrough What the compound did reliably do was label and bind receptors in living tissue — in a way that made receptor location and accessibility visible. This solved a long-standing problem in GPCR biology: You can't understand signaling if you can’t see where the receptor actually is. For decades, GPCR localization relied on: Antibodies of inconsistent specificity Fixed tissue sections Indirect signaling readouts Researchers in the field know this frustration intimately: an antibody works in one context and fails entirely in another. Knockouts don’t behave as expected. Live-tissue dynamics become guesswork. This accidental tool changed that. It enabled: Live-tissue visualization Cell-type-specific receptor mapping Validation in both the periphery and brain Being able to see receptor distribution is not just aesthetic — it shifts interpretation. For metabolic GPCRs (like GLP-1 and GIP receptors): Drug efficacy depends on which cells express the receptor Side effects are tied to where agonists bind Weight-loss and appetite effects often originate in precise brain regions, not just the pancreas This tool helped clarify: Which neurons respond Which cell populations drive therapeutic benefit Where not  to target to avoid adverse effects Why GPCR Imaging Tools Matter More Than Ever This tool could not have emerged from a single lab. It happened because Hodson and JB thought differently — and allowed the clash of disciplines to be productive. Hodson: physiology, disease context, and imaging logic JB: chemistry, ligand engineering, mechanistic boldness Their collaboration worked not because they were aligned — but because they were complementary. And importantly, they liked working together. We’re not here long enough to spend 30 years collaborating with people we don’t enjoy. This is the part labs often underplay: scientific culture shapes scientific possibility. Collaboration, Chemistry, and the Pivot That Changed the Project Goal:  Develop a photo-switchable GPCR ligand Result:  The switching didn’t work Observation:  Binding + localization were unexpectedly robust Reframing:  Use the compound as a visualization tool Impact:  Shared widely → now used globally to map GPCR activity in live systems The success wasn’t in the discovery. It was in recognizing that the failure was useful. The Larger Lesson for Scientists and Innovators This story isn’t just about a GPCR imaging tool. It’s about how translation happens. Experiments fail for reasons that contain information. “Negative data” isn’t negative — it’s directional. The most valuable outputs often come from the “wrong” projects. For Early-Career Scientists Don’t optimize your trajectory for papers. Optimize it for questions that won’t leave you alone. Scientific progress is rarely linear. But depth compounds. What Changed After This Data This imaging tool is now being used to: Re-evaluate where GLP-1 and GIP receptors matter most Clarify brain vs. peripheral contributions to metabolic therapy Guide how next-generation incretin drugs are designed Support cell-targeted conjugate therapeutic strategies It didn’t just solve a problem. It opened a new category of problems to solve more efficiently. Which is the real definition of impactful science. This conversation is part of a three episode series produced in collaboration with our partners at Celtarys Research . If this story resonates with your work or curiosity, go deeper. 🎧 Listen to the full conversation with Dr. David Hodson

Dr. GPCR Podcast - The Voice of the Community Whether you’re a scientist, student, or just curious, you’ll hear about discoveries, career stories, and the latest GPCR news. Jump in and get inspired! Strategic Partners Latest Podcast Episodes 2025-11-19 2025-09-22 2025-08-05 2025-06-11 2025-04-29 2025-09-02 2025-07-22 2025-05-27 2025-10-22 2025-08-19 2025-07-08 2025-05-13 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 ... 8 Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player Listen and subscribe where you get your podcasts

Discover the Dr. GPCR Ecosystem, where we connect and empower the GPCR community in the United States. Home: About Accelerating GPCR Drug Discovery, Together Dr. GPCR is the global hub where academia and industry meet to advance GPCR research, accelerate drug discovery, and foster collaboration across the entire ecosystem. 👉 Join Free Today 🔒 Go Premium Strategic Partners Your Path to GPCR Mastery Flexible, career-ready courses designed by scientists for scientists. GPCR Courses ➚ GPCR Weekly News ➚ Dr. GPCR Podcast ➚ Articles from the Ecosystem ➚ The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands How a Failed Experiment Created a Powerful GPCR Imaging Tool From Farm Fields to GPCR Discovery, GLP-1 and GIP GPCR Flash News ➚ Closing the Gap Between Academia and Industry Our vision is simple: empower the GPCR field through shared knowledge, collaboration, and open access to tools that accelerate drug discovery. 🤝 Support the Mission Home: Premium $ 249.99 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Select 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. 🔒 Grandfather Guarantee, your rate never increases Everything You Need to Master GPCR Science in One Membership Join the most complete GPCR learning & collaboration hub. Closing the Gap Between Academia and Industry Our vision is simple: empower the GPCR field through shared knowledge, collaboration, and open access to tools that accelerate drug discovery. 🤝 Support the Mission

Explore the world of GPCRs with Dr. GPCR Podcast! Join industry leaders as they share insights, stories, and groundbreaking discoveries, enriching our understanding of GPCRs. Delve into the science behind these vital components shaping our collective knowledge. Welcome to the Dr. GPCR Podcast - The Voice of the Community Conversations with the world’s leading GPCR scientists. Exploring discoveries, careers, and ideas shaping human health. In each episode, we sit down with leading experts to explore their career journeys, groundbreaking discoveries, and the impact of their research on our shared understanding of GPCR biology. Launched at the height of the pandemic, the Dr. GPCR Podcast was created with three goals: Share discoveries – Highlight the latest advances in the GPCR field. Amplify voices – Provide scientists a platform to showcase their work. Inspire the future – Motivate the next generation to pursue GPCR research. At its core, Dr. GPCR’s mission is simple yet ambitious: to bring the GPCR community together - across borders and disciplines - to connect, exchange, and collaborate in order to improve human health through a deeper understanding of GPCR biology. Latest Podcast Episodes More podcast episodes Dr. GPCR Podcast Audience Survey We are currently planning our next season and need your help. This short survey will help us understand your needs to bring you exciting and informative content. We also know that you are busy, which is why we designed this short survey that should take you 5 minutes. Fill out this form Be our Guest In each episode, we chat with an expert about their career trajectory, discoveries, and how their research contributed to the shared pool of knowledge about GPCR biology. We’d love to have you on our podcast. To be a guest, fill out the form below, and we’ll be in touch in 48 hours. Fill out this form What others are saying about this podcast Really enjoyable science podcast! Dr. Yamina Berchiche interviews leading GPCR scientists on this vibrant, entertaining podcast. I really appreciate the way the podcast educates and mentors, particularly towards junior scientists but also to the community as a wholen Yamina is a great interviewer, getting insight and personal history from her guests. Am very grateful for Dr GPCR livening up the week in these difficult times! Sam @Pharmamechanic I enjoy the breadth of questioning that goes beyond just the science, and reveals a bit about the scientists as individuals/mentors/people. Anonymous Great initiative, thanks. Carrier paths, choosing research topics, switching fields, late start, failures and successes. Anonymous This came at just the most perfect time. I hadn't heard a scientific talk outside my lab since February and was starved to hear someone else talk passionately about GPCRs. I've listened to the episodes multiple times and it's just like being at a conference getting new ideas. I just couldn't be happier y'all created this podcast. Anonymous I think it's really well done. I'm genuinely interested to see how it evolves and grows over time, as I feel it has the potential to develop into something even more impactful. Anonymous Listen and subscribe where you get your podcasts